Literature DB >> 34344757

Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Bérengère Salomé1, Amir Horowitz2.   

Abstract

Cancer is a strong risk factor for severe COVID-19 disease. In this issue of Cancer Discovery, Bilich and colleagues demonstrate impaired preexisting and newly generated CD4 T-cell response to SARS-CoV-2 in patients with cancer.See related article by Bilich et al., p. 1982. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID： 34344757     DOI： 10.1158/2159-8290.CD-21-0613

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  5 in total

1.  Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol.

Authors:  Nicola Silvestris; Valeria Belleudi; Antonio Addis; Fulvia Pimpinelli; Aldo Morrone; Salvatore Sciacchitano; Rita Mancini; Vito Michele Garrisi; Massimo Costantini; Gennaro Ciliberto; Vincenza Frisardi; Giulia Piaggio
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 2.  CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 3.  The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells.

Authors:  Yifei Wang; Qin Tian; Lilin Ye
Journal:  Front Cell Infect Microbiol       Date:  2022-07-14       Impact factor: 6.073

4.  Case report: Nocardial brain abscess in a persistently SARS-CoV-2 PCR positive patient with systemic lupus erythematosus.

Authors:  Jelena Veličković; Tatjana Adžić Vukičević; Aleksandra Radovanović Spurnić; Igor Lazić; Bojana Popović; Ivan Bogdanović; Savo Raičević; Dragana Marić; Ivana Berisavac
Journal:  Front Med (Lausanne)       Date:  2022-08-18

5.  Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).

Authors:  Sabrina Jotschke; Susann Schulze; Nadja Jaekel; Beatrice Ludwig-Kraus; Robby Engelmann; Frank Bernhard Kraus; Christina Zahn; Nicole Nedlitz; Gabriele Prange-Krex; Johannes Mohm; Bettina Peuser; Maik Schwarz; Claudia Spohn; Timo Behlendorf; Mascha Binder; Christian Junghanss; Sebastian Böttcher; Haifa Kathrin Al-Ali
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.